CL2 Linker Chemical Structure
CAS No. : 2270986-66-6
Acid cleavable linker
ADC-Related Custom Services
MedChemExpress (MCE) owns a strong technical team and state-of-the-art facilities. For ADC products, we have rich experience in research development and production. MCE can provide one-stop services for the design, synthesis, analysis, purification, optimization, detection and evaluation of ADC-related products (ADC Cytotoxin, ADC Linker, Drug-Linker Conjugates for ADC and Antibody-drug Conjugate (ADC)).
The MCE conjugated drug technology platform has the R&D and production capabilities for various types of conjugated drugs. MCE is able to provide one-stop services for PAC, AOC, PDC, ApDC, FDC, RDC, ISAC, VDC, SMDC and other related products. MCE relies on its strong organic synthesis capabilities and rich drug conjugation experience to assist the research and development of XDC drugs.
ADC Cytotoxin
ADC Linker
Drug-Linker Conjugates
for ADC
for ADC
Conjugation Strategy
ADCs
(1) ADC Cytotoxin related services
ADC Cytotoxin: custom synthesis service
ADC Cytotoxin: structure modification service
(1) Achieved a breakthrough in the total synthesis technology of Eribulin (CAS: 441045-17-6), completed process development, pilot production, hundred-gram level GMP process verification and stability testing of APIs and advanced intermediates;
(2) Compared with the original drug, the API obtained through the process has characteristic impurity limits below 0.10%;
(3) Achieving stable supply of hundred grams level of advanced eribulin intermediates and API under GMP system and non-GMP system.
(2) Compared with the original drug, the API obtained through the process has characteristic impurity limits below 0.10%;
(3) Achieving stable supply of hundred grams level of advanced eribulin intermediates and API under GMP system and non-GMP system.
The selection of Payloads
The payloads are the ultimate effector components of therapeutic antibody-drug conjugates (ADCs). Ideally, the potency of the cytotoxic payload should be extremely high. Also, they should have reasonable solubility, sufficient stability, low immunogenicity, and a long half-life.
(2) ADC Linker related services
ADC Linker: custom synthesis service
ADC Linker: structure modification service
MC-Val-Cit-PAB Chemical Structure
CAS No. : 159857-80-4
Enzyme cleavable linker
SMCC Chemical Structure
CAS No. : 64987-85-5
Non-cleavable linker
MCE provides customized synthesis and structural modification services for two types of linkers (cleavable linkers and non-cleavable linkers). Cleavable linkers include chemically cleavable linkers (such as acid-labile linkers, disulfide linkers, etc.) ) and enzyme-cleavable linkers (e.g., peptide linkers and β-glucuronide linkers).
The selection of Linkers
An ideal linker between the cytotoxic payload and the antibody should be stable in circulation. At the same time, it must rapidly and efficiently release the cytotoxic agent inside the tumor cells. In addition, it needs to possess high hydrophilicity.
(3) Drug-Linker Conjugates for ADC related services
Drug-Linker Conjugates for ADC: custom synthesis service
Drug-Linker Conjugates for ADC: structure modification service
VcMMAE HY-15575
VcMMAE (mc-vc-PAB-MMAE) is a part of the antibody conjugate active molecule (drug-linker conjugate for ADC) with anti-cancer activity. It is connected by MMAE (a tubulin inhibitor) and valine-citrulline (vc) .
The selection of Drug-Linker Conjugates for ADC
Drug-linker conjugates, which consist of a cytotoxic payload and an appropriate linker, can be directly linked to monoclonal antibodies, composing the immunoconjugates for cancer therapy.
(4) Conjugation Strategy related services
Conventional Conjugation: cysteine-based conjugation, lysine-based conjugation, etc.
Site-specific Conjugation: Thiomab site-specific conjugation, unnatural amino acids and various enzyme-catalyzed site-specific conjugation, etc.
| Conjugation Strategies | Schematic Diagram | |
|---|---|---|
|
Stochastic conjugation[1] |
Lysine sites |
|
| Reduced cysteine sites |
|
|
|
Site-specific conjugation[1][2] |
Engineered reactive cysteine residues |
|
| Disulfide re-bridging |
|
|
| Unnatural amino acids |
|
|
| Enzyme-assisted ligation |
|
|
| Glycan remodeling and glycoconjugation |
|
|
| AbClick |
|
|
The selection of Conjugation strategies
The conjugation method in ADC drugs directly determines the drug-to-antibody ratio (DAR), the distribution of conjugation sites, conjugation stability, and other properties.
(5) ADCs related services
Custom Synthesis: design and synthesize ADCs
ADC Characterization: detection of drug-to-antibody ratio (DAR), free drug, endotoxin, etc.
Derived services
Antibody-oligonucleotide conjugate (AOC)
AOC consists of three parts: antibody, linker and oligonucleotide. AOC combines the tissue-specific targeting of antibody drugs with the target-specific capabilities of small nucleic acids, addressing the limitation of current small nucleic acid drugs that mainly target the liver through LNP and GalNAc delivery systems.
MCE provides custom coupling services for AOC, offering a diverse selection of small interfering RNA (siRNA) and antisense oligonucleotides (ASO) . We also provide customization and chemical modification services for oligonucleotides, covering phosphorothioate, 2 '-F, 2'-OMe, and 2'-MOE, etc.
PROTAC-antibody conjugate (PAC)
PROTAC stands for proteolysis-targeting chimeras (protein degradation targeting chimeras), a hybrid bifunctional small molecule compound. PROTAC molecules generally consist of three parts: a target protein ligand, a linker, and an E3 protein ligase ligand. PROTACs use the "ubiquitin-proteasome" pathway to specifically degrade target proteins by bringing the target protein closer to the intracellular E3 ubiquitin ligase. PROTAC-antibody conjugate (PAC) enhances targeting, enabling selective degradation of target proteins in specific cell types.
MCE provides custom synthesis services for PROTAC and related products.
Peptide-drug conjugate (PDC)
PDC consists of three parts: cytotoxin, linker, and targeting peptide. PDC integrates the advantages of polypeptides such as small molecular weight, biodegradability, and does not cause immunogenic reactions. It can modify the amino acid sequence of the peptide chain to change the conjugation hydrophobicity and ionization properties to solve problems such as poor water solubility and untimely metabolism.
MCE provides customized peptide synthesis services and structural modification (amidation, acetylation, methylation, phosphorylation, etc.) services.
Aptamer-drug conjugate (ApDC)
ApDC is composed of nucleic acid aptamer, linker, and small molecule drug. It uses nucleic acid aptamers to replace the targeting role of antibodies in traditional ADCs. Aptamers are short single-stranded DNA or RNA that can bind to variety of targets, such as proteins, peptides, carbohydrates, and other molecules, by virtue of their tertiary structure, rather than their sequence.
MCE provides a variety of nucleic acid aptamer selections and custom synthesis services.
Antibody fragment-drug conjugate (FDC)
FDC consists of antibody fragments conjugated to cytotoxic drugs. Due to the small molecular weight of antibody fragments, FDC has better tumor penetration. The short half-life of FDC reduces its exposure in normal tissues and improves safety.
MCE provides custom synthesis and structural modification services for antibody fragments.
Radionuclide-drug conjugate (RDC)
RDC consists of antibodies or small molecules, linkers, chelates, and radionuclide. The feature of RDC is that the drug load is radionuclides instead of small molecules, achieving the purpose of precise radiotherapy, killing tumors while reducing radiation to normal tissues, thereby reducing side effects.
Immune-stimulating antibody conjugate (ISAC)
ISAC consists of three parts: an antibody, a linker, and an immunostimulator. The unique feature of ISAC is that the payload is an innate immune agonist or modulator. The commonly used immune stimulators are TLR7,
TLR8, TLR9 agonists or STING agonists. Activating CD4/CD8 T cells through TLR converts cold tumors into immune-hot tumors, thereby activating immune killing and achieving the purpose of treating tumor diseases.
Virus-like drug conjugate (VDC)
VDC is conjugated drug forms that use viral capsids designed as non-infectious protein nanoparticles (virus-like particle, VLP), as efficient delivery carriers.
VLP is small nanoparticles made of viral capsid proteins connected to cytotoxic drugs, which serves as the targeting system in VDC drugs to target tumor cells and exert anti-tumor effects.
VDC is structurally complex, and both overall biological certainty and technological development are at an early stage.
VLP is small nanoparticles made of viral capsid proteins connected to cytotoxic drugs, which serves as the targeting system in VDC drugs to target tumor cells and exert anti-tumor effects.
VDC is structurally complex, and both overall biological certainty and technological development are at an early stage.
Small molecule-drug conjugate (SMDC)
SMDC is composed of three parts: small molecule targeting ligand, linker, and effector molecules (cytotoxic molecule, E3 ligase, etc.). Small molecule targeting ligands have a small molecular weight, which penetrate more easily and diffuse more evenly into tumor tissues to achieve tumor-killing effects.
The MCE conjugated drug technology platform has single-batch production capabilities from milligrams to hundreds of grams, and provides one-stop service from customized products to registration and application, to GMP commercial production.
Our Advantages
We have more than 1600+ ADC-related products. We have the strong ability and rich experience in the synthesis of highly complex compounds, and perform the design and synthesis of payloads and linkers. We developed new synthetic process routes by continuous technological innovation, and established cooperative relations with well-known pharmaceutical enterprises such as Abbvie and AstraZeneca.
-
Covenient delivery
The finished products can be delivered for use at the first time, reducing the intermediate links. -
Price concessions
ADC products have high cost performance and favorable prices. -
Product reports
MedChemExpress (MCE) provide you with real and reliable experimental data related to ADCs. -
In strict confidence
After confirming ADC products, MedChemExpress and you will sign a confidentiality aggrement, and your information enjoys absolute security. -
Free consultation
For-presales and after-sales consultation of ADC products, professional ADC technicians will answer your questions and solve your doubts for free.
Service and Consulting
The corresponding scheme and price for ADC-related custom services shall be determined after evaluation. For further information on service pricing or technical details,
please email [email protected] or contact MedChemExpress sales staff directly.